Methylprednisolone acetate
As of the edition of 20 October 2026, Methylprednisolone acetate is a small molecule: marketed, first approved in 1960 (CA); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Depo-Medrol
- First approved
- 31 December 1960 (CA)
- Approvals on record
- 12 in 2 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 31, 4 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system; Injuries; Mental health; Skin and connective tissue; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 5 | 2 | 1 |
| Phase 2 | 3 | 1 | 2 | 0 |
| Phase 3 | 9 | 4 | 3 | 0 |
| Phase 4 | 7 | 2 | 1 | 3 |
| All trials | 31 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 1960 to now |